Targeting bile-acid signalling for metabolic diseases

By Charles Thomas, R. Pellicciari, M. Pruzanski, Johan Auwerx, K. Schoonjans. Nature reviews. Drug discovery, 2008

1,345 citations recorded by the source corpus.

Subfields: Epidemiology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/f72bdea54984af8f2a5d422191bfd89e130bab98

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Oncology

In Surgery

Citations in the corpus

Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. (2016, positive): “The classical (or neutral) pathway accounts for at least 75% of bile acid production under normal conditions and is initiated by 7a-hydroxylation of cholesterol catalyzed by cholesterol 7a-hydroxylase (CYP7A1) (Thomas et al., 2008).”
Mechanisms and consequences of intestinal dysbiosis (2017, background): “Binding to FXR not only regulates bile acid synthesis but also influences lipid, glucose and energy homeostasis [50].”
Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. (2016, background): “Bile acids (BAs) are a diverse class of cholesterol-derived, amphipathic molecules that function both as detergents to facilitate the digestion and absorption of dietary lipids, and as hormones endowed with systemic endocrine functions (de Aguiar Vallim et al., 2013; Fiorucci and Distrutti, 2015; Ru”
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. (2013, background): “Keywords: Clinical Trial; Metabolic Syndrome; Treatment; Obesity. ype 2 diabetes mellitus and nonalcoholic fatty liver Tdisease (NAFLD) are components of the metabolic syndrome, a cluster of interrelated clinical features including insulin resistance, dyslipidemia, hypertension, and visceral obesity”
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2018, background): “(157,158) In animal models, FXR activation has demonstrated antifibrotic and anti-inflammatory properties as well.(157) A phase 2 randomized controlled trial evaluated 3 doses of OCA (10 mg, 25 mg, and 50 mg) against placebo for 3 months in a study including 165 patients.”
Bile acids: regulation of synthesis (2009, background): “of cAMP, which induces iodothyrone deiodinase (D2) and production of thyroid hormone T3 leading to stimulation of energy metabolism and improving glucose tolerance and insulin sensitivity (10, 12, 37).”
TGR5-mediated bile acid sensing controls glucose homeostasis. (2009, background): “The complete absence of changes in the expression level of classical target genes of FXR in the liver, such as cholesterol 7a hydroxylase (CYP7A1) and bile salt export pump (BSEP) (Thomas et al., 2008), further confirmed the specificity of INT-777 toward TGR5 (Figure S6B).”
Pleiotropic Roles of Bile Acids in Metabolism (2013, background): “, OAT1B2) that mediate the uptake of bile salts and bile acids, respectively (Figure 2A) (Chiang, 2009; Thomas et al., 2008).”
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease (2011, background): “Currently, phase 1 and 2 studies with INT-747 are being performed in patients with metabolic and chronic liver diseases, indicating the safe applicability of this class of compounds for the treatment of human disease.(42) Figure 8 INT-747 inhibits IFNg, IL-17 and TNFa production by lymphocyte-enrich”